Raynaud's phenomenon: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
No edit summary
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
No edit summary
Line 14: Line 14:
}}
}}


{{SI}}
{{Raynaud's phenomenon}}


'''Editors-In-Chief:''' Asghar Fakhri, M.D., Duane S. Pinto, M.D. and C. Michael Gibson, M.S., M.D.
'''Editors-In-Chief:''' Asghar Fakhri, M.D., Duane S. Pinto, M.D. and C. Michael Gibson, M.S., M.D.

Revision as of 17:04, 21 August 2012

For patient information click here

Raynaud's phenomenon
Hands with Raynaud's phenomenon
ICD-10 I73.0
ICD-9 443.0
DiseasesDB 25933
MeSH D011928

Raynaud's phenomenon Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Raynaud's phenomenon from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Raynaud's phenomenon On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Raynaud's phenomenon

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Raynaud's phenomenon

CDC onRaynaud's phenomenon

Raynaud's phenomenon in the news

Blogs on Raynaud's phenomenon

Directions to Hospitals Treating Raynaud's phenomenon

Risk calculators and risk factors for Raynaud's phenomenon

Editors-In-Chief: Asghar Fakhri, M.D., Duane S. Pinto, M.D. and C. Michael Gibson, M.S., M.D.

Overview

Raynaud's phenomenon (RAY-noz), in medicine, is a vasospastic disorder causing discoloration of the fingers, toes, and occasionally other extremities, named for French physician Maurice Raynaud (1834 - 1881). The cause of the phenomenon is unknown, but emotional stress and cold are classically triggers, and the discoloration follows a characteristic pattern in time: white, blue and red. It comprises both Raynaud's disease (primary Raynaud's), where the phenomenon is idiopathic, and Raynaud's syndrome (secondary Raynaud's), where it is secondary to something else.

Incidence

The phenomenon is more common in women than men, with the Framingham Study finding that 5.8% of men and 9.6% of women suffered from it.

Epidemiology

There is a familial component to primary Raynaud's, and presentation is typically before 30. Smoking worsens frequency and intensity of attacks, and there is a hormonal component. Sufferers are more likely to have migraine and angina than controls.

Associated Conditions

Secondary Raynaud's has a number of associations:

It is important to realise that Raynaud's can herald these diseases by periods of more than 20 years in some cases, making it effectively their first presenting symptom. This can be the case in the CREST syndrome, of which Raynaud's is a part.

Diagnosis

Physical Examination

  • Raynaud's Phenomenon
    Raynaud's Phenomenon

Complete List of Differential Diagnoses

In alphabetical order [1][2]

Symptoms

The condition causes painful, pale, cold extremities. This is often distressing, impinges on quality of life, and is potentially dangerous

Unilateral Raynaud's, or that which is present only in the hands or feet, is almost certainly secondary, as primary Raynaud's is a systemic condition. However, a patient's feet may be affected without his realizing it.

In pregnancy, this sign normally disappears due to increased surface blood flow.

Investigations

A careful history will often reveal whether the condition is primary or secondary. Once this has been established, investigations are largely to identify or exclude possible secondary causes.

Laboratory Findings

  • Labs include:

Autoantibody Testing

  • Anti-double stranded DNA and anti - Sm
  • Anti - Sjögren's syndrome
  • Anti - CREST syndrome
  • Anti - ribonucleoprotein
  • Anti - Scl 70
  • ANCA

Treatment

Treatment options are dependent on the type of Raynaud's present. Raynaud's syndrome is treated primarily by addressing the underlying cause, but includes all options for Raynaud's disease as well. Treatment of primary Raynaud's focuses on avoiding triggers:

  • Avoidance of any environmental triggers, e.g. cold, drilling, etc. (although emotional stress is a recognised trigger, it tends to be impossible to consciously avoid).
  • Warm clothing for the extremities such as mittens or HeatBands
  • Hormone regulation and assessment of the type of hormonal contraception used, if any. Contraception which is low in estrogen is preferable, and the progesterone only pill is often prescribed.
  • Smoking cessation.
  • Drug treatment is normally with a calcium channel blocker, frequently nifedipine to prevent arterioconstriction. It has the usual side effects of headache, flushing, and ankle edema, and patients often stop treatment, preferring the symptoms of Raynaud's to the symptoms of the drug.
  • The extract of the Ginkgo biloba leaves (Egb 761, 80mg) reduces symptoms in two weeks.
  • There is some evidence that Angiotensin II receptor antagonists (often Losartan) reduce frequency and severity of attacks.
  • In intractable cases, sympathectomy and infusions of prostaglandins, e.g. prostacyclin, may be tried, with amputation in exceptionally severe cases.
  • Alpha-1 adrenergic blockers such as prazosin can be used to control Raynaud's vasospasms under supervision of a health care provider.
  • In a study published in the November 8, 2005 issue of Circulation, sildenafil (Viagra) improved both microcirculation and symptoms in patients with secondary Raynaud's phenomenon resistant to vasodilatory therapy. The authors, led by Dr Roland Fries (Gotthard-Schettler-Klinik, Bad Schönborn, Germany), report: "In the present study, capillary blood flow was severely impaired and sometimes hardly detectable in patients with Raynaud's phenomenon. Sildenafil led to a more than 400% increase of flow velocity."
  • Two separate gels combined on the fingertip (somewhat like two-part epoxy, they cannot be combined before use because they will react) increased blood flow in the fingertips by about three times. One gel contained 5% sodium nitrite and the other contained 5% ascorbic acid. The milliliter of combined gel covered an area of ~3 cm². The gel was wiped off after a few seconds. Tucker, A.T. et al., The Lancet, Vol. 354, November 13, 1999, pp..

See also

References

  1. ↑ Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:144
  2. ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:310-311

External links

de:Raynaud-Syndrom ko:레이노 현상 it:Fenomeno di Raynaud nl:Fenomeen van Raynaud fi:Raynaud'n oireyhtymä


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Raynaud%27s_phenomenon&oldid=692506"